Sort
82,697 grants matching “vaccine development”
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · SB1 · FY2023 · AI
Seriodiagnostic arrays for biodefense and emerging infectious diseases
$1,000,000David Huw Davies · Immport Therapeutics, Inc. · R44 · FY2009 · AI
A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products
$1,000,000Peter F. Billingsley · Sanaria, Inc. · R44 · FY2023 · AI
Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)
$1,000,000Xiaowu Pang · Tengen Biomedical Co. · R42 · FY2021 · AI
Corral 9 renovation to support SPF NHP breeding
$999,999Peter Gordon Gillespie · Oregon Health & Science University · P51 · FY2021 · OD
Improving the Efficacy of Dendritic Cell Vaccines
$999,999Jacques F Banchereau · Baylor Research Institute · P01 · FY2006 · CA
Technology for Culture of Megathura crenulata for KLH
$999,999David C Spaulding · Stellar Biotechnologies, Inc. · R44 · FY2006 · CA
SIRPant Technology for anti-Cancer Immunity
$999,999Nathanael McCurley · Bobcatbio, Inc. · R42 · FY2024 · CA
Optimization of a DNA Subunit Regimen for an HIV Vaccine
$999,999Timothy R Fouts · Profectus Biosciences, Inc. · R44 · FY2014 · AI
Technology for Culture of Megathura crenulata for KLH
$999,999Stellar Biotechnologies, Inc. · R44 · FY2004 · CA
Development of the first HRV vaccine
$999,998Gregory John Tobin · Biological Mimetics, Inc. · R44 · FY2016 · AI
Preclinical development of a potent D-peptide RSV inhibitor
$999,998Brett D Welch · Navigen, Inc. · R44 · FY2017 · AI
Cryopreservation of Anopheles Embryos
$999,998Peter F. Billingsley · Sanaria, Inc. · R44 · FY2014 · AI
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
$999,998Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2025 · AI
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$999,998Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2021 · AI
Preclinical development of a potent D-peptide RSV inhibitor
$999,998Brett D Welch · Navigen, Inc. · R44 · FY2018 · AI
Development of the first HRV vaccine
$999,998Gregory John Tobin · Biological Mimetics, Inc. · R44 · FY2015 · AI
PIPP Phase I: Predicting and Preventing Epidemic to Pandemic Transitions
$999,997Ioannis Paschalidis · Trustees Of Boston University · · FY2022 · BIO
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
$999,997Rajan P Adhikari · Integrated Biotherapeutics, Inc. · R42 · FY2019 · AI
Genetically Attenuated PfSPZ Malaria Vaccine
$999,997Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2017 · AI
Cryopreservation of Anopheles Embryos
$999,997Peter F. Billingsley · Sanaria, Inc. · R44 · FY2020 · AI
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
$999,997Gary G. Altman · Cambium Oncology Llc · R44 · FY2025 · CA
In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine
$999,997Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2017 · AI
In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine
$999,997Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2016 · AI
In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine
$999,996Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2015 · AI